Abalone Bio

Abalone Bio

  • Founded: 2017
  • Location: Emeryville , CA
  • Employee range: 11 - 50
  • Clinical stage: Clin0
  • Therapy area: Diabetic peripheral neuropathic pain
  • Drug types: PN, LNG, INF, HEP, GI, ONC, NPH, END, NWL
  • Lead product: Undisclosed
  • Product link: https://www.abalonebio.com/programs
  • Funding: <10M



job board

Short description:

Antibody Therapies

Drug notes:

Undisclosed Clin0 liver fibrosis/NASH; undisclosed Clin0 lung conditions/influenza; undisclosed Clin0 IBD; 5 undisclosed programs RD immuno-oncology, polycystic kidney disease, obesity, diabetes

Long description:

Abalone Bio is developing antibody drugs that target receptors on the surface of cells to treat diseases. G-protein coupled receptors (GPCRs) are important for cellular health and frequently get disrupted in disease, yet many remain undruggable by small molecules. Antibodies are also limited to only blocking, not activating, GPCRs. Abalone is changing this by finding both activating or inhibiting bioactive antibodies that target GPCRs. To discover these antibodies, Abalone is combining engineered living cells with data-driven computation, which is compatible with different types of antibodies. Abalone’s first therapeutic focus is immune system regulators that cause inflammatory diseases and cancer.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com